ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

CRIS Curis Inc

14,47
-0,05 (-0,34%)
27 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Curis Inc CRIS NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,05 -0,34% 14,47 06:00:04
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
14,44 14,25 14,6899 14,47 14,52
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
05.4.202413:30PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
04.4.202413:30PRNUSCuris to Present at Upcoming Healthcare Conferences in April
12.2.202422:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08.2.202422:36EDGAR2Form S-8 - Securities to be offered to employees in employee..
08.2.202422:27EDGAR2Form S-3 - Registration statement under Securities Act of..
08.2.202422:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08.2.202414:01EDGAR2Form 8-K - Current report
08.2.202414:00PRNUSCuris Provides Fourth Quarter 2023 Business Update
01.2.202414:00PRNUSCuris to Release Fourth Quarter 2023 Financial Results and..
11.1.202414:13EDGAR2Form 8-K - Current report
05.1.202414:00PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
21.12.202322:00EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
12.12.202314:00PRNUSCuris Announces Initial Combination Study Data from its..
11.12.202314:00PRNUSCuris Presented Clinical Data from the TakeAim Leukemia..
06.12.202314:00PRNUSCuris Announces Three Presentations at ASH
05.12.202314:00PRNUSCuris Enters into Agreement for Emavusertib / Pembrolizumab..
02.11.202313:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02.11.202313:01EDGAR2Form 8-K - Current report
02.11.202313:00PRNUSCuris Provides Third Quarter 2023 Business Update
26.10.202314:30PRNUSCuris to Release Third Quarter 2023 Financial Results and..
06.10.202314:56PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
28.9.202322:05EDGAR2Form 8-K/A - Current report: [Amend]
28.9.202314:54EDGAR2Form 8-K - Current report
12.9.202314:00PRNUSCuris Announces Date for the 2nd Symposium on IRAK4 in..
06.9.202314:13PRNUSCuris to Present at Upcoming Healthcare Conferences in..
18.8.202322:02EDGAR2Form DEF 14A - Other definitive proxy statements
04.8.202322:09EDGAR2Form PRE 14A - Other preliminary proxy statements
03.8.202322:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03.8.202322:02EDGAR2Form 8-K - Current report
03.8.202322:01PRNUSCuris Provides Second Quarter 2023 Business Update
28.7.202300:25PRNUSCuris to Release Second Quarter 2023 Financial Results and..
06.7.202322:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06.7.202315:28EDGAR2Form 8-K - Current report
06.7.202314:04EDGAR2Form 8-K - Current report
06.7.202314:01PRNUSFDA Removes Partial Clinical Hold on TakeAim Leukemia Study..
06.7.202314:00PRNUSCuris Announces $15.1 Million Registered Direct Offering
05.5.202313:30PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
04.5.202322:01PRNUSCuris Provides First Quarter 2023 Business Update

Kürzlich von Ihnen besucht

Delayed Upgrade Clock